Three new exclusive option license agreements expand the depth and breadth of ONK’s pre-clinical pipeline A humanized scFv targeting CLEC12A licensed from Cellerant Therapeutics, creates a fourth ...
GALWAY, Ireland, & SAN DIEGO, Calif.--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has secured three new exclusive option ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback